GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Reshape Lifesciences Inc (NAS:RSLS) » Definitions » Cyclically Adjusted PB Ratio

RSLS (Reshape Lifesciences) Cyclically Adjusted PB Ratio : 0.00 (As of May. 30, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Reshape Lifesciences Cyclically Adjusted PB Ratio?

As of today (2025-05-30), Reshape Lifesciences's current share price is $4.91. Reshape Lifesciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $10,231.61. Reshape Lifesciences's Cyclically Adjusted PB Ratio for today is 0.00.

The historical rank and industry rank for Reshape Lifesciences's Cyclically Adjusted PB Ratio or its related term are showing as below:

During the past years, Reshape Lifesciences's highest Cyclically Adjusted PB Ratio was 28.49. The lowest was 0.01. And the median was 0.30.

RSLS's Cyclically Adjusted PB Ratio is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.82
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Reshape Lifesciences's adjusted book value per share data for the three months ended in Mar. 2025 was $9.248. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $10,231.61 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Reshape Lifesciences Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Reshape Lifesciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reshape Lifesciences Cyclically Adjusted PB Ratio Chart

Reshape Lifesciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 8.50 0.76 0.03 0.01

Reshape Lifesciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.03 0.01 0.01 -

Competitive Comparison of Reshape Lifesciences's Cyclically Adjusted PB Ratio

For the Medical Devices subindustry, Reshape Lifesciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Reshape Lifesciences's Cyclically Adjusted PB Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Reshape Lifesciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Reshape Lifesciences's Cyclically Adjusted PB Ratio falls into.


;
;

Reshape Lifesciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Reshape Lifesciences's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=4.91/10231.61
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Reshape Lifesciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Reshape Lifesciences's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=9.248/134.9266*134.9266
=9.248

Current CPI (Mar. 2025) = 134.9266.

Reshape Lifesciences Quarterly Data

Book Value per Share CPI Adj_Book
201506 1,432.000 100.684 1,919.025
201509 7,742.000 100.392 10,405.281
201512 3,673.000 99.792 4,966.164
201603 -1,259.000 100.470 -1,690.773
201606 -3,610.000 101.688 -4,789.990
201609 1,155.000 101.861 1,529.930
201612 2,939.000 101.863 3,892.978
201703 17,946.000 102.862 23,540.161
201706 37,995.000 103.349 49,604.072
201709 51,037.000 104.136 66,127.711
201712 76,366.000 104.011 99,064.472
201803 65,873.000 105.290 84,415.064
201806 39,109.000 106.317 49,633.213
201809 7,209.600 106.507 9,133.386
201812 433.726 105.998 552.097
201903 446.250 107.251 561.405
201906 56.265 108.070 70.248
201909 -44.246 108.329 -55.109
201912 61.495 108.420 76.529
202003 55.018 108.902 68.166
202006 3.428 108.767 4.252
202009 3.057 109.815 3.756
202012 2.349 109.897 2.884
202103 2.060 111.754 2.487
202106 9.424 114.631 11.092
202109 12.846 115.734 14.976
202112 7.189 117.630 8.246
202203 6.263 121.301 6.967
202206 5.248 125.017 5.664
202209 3.396 125.227 3.659
202212 0.594 125.222 0.640
202303 3,879.000 127.348 4,109.849
202306 3,369.000 128.729 3,531.207
202309 1,541.500 129.860 1,601.649
202312 416.438 129.419 434.159
202403 283.375 131.776 290.150
202406 151.750 132.554 154.466
202409 53.107 133.029 53.865
202412 -8.724 133.157 -8.840
202503 9.248 134.927 9.248

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Reshape Lifesciences  (NAS:RSLS) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Reshape Lifesciences Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Reshape Lifesciences's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Reshape Lifesciences Business Description

Traded in Other Exchanges
N/A
Address
18 Technology Drive, Suite 110, Irvine, CA, USA, 92618
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States.
Executives
Thomas Stankovich officer: Chief Financial Officer 1001 CALLE AMANECER, SAN CLEMENTE CA 92673
Paul F. Hickey director, officer: President and CEO 2800 PATTON ROAD, ST. PAUL MN 55113
Barton P. Bandy director 1001 CALLE AMANECER, SAN CLEMENTE CA 92673
Mcdougal Lori Courtney director 2800 PATTON ROAD, ST. PAUL MN 55113
Arda Phd Minocherhomjee director C/O CHICAGO GROWTH PARTNERS, 303 W MADISON ST., SUITE 2500, CHICAGO IL 60606
Dan W Gladney director 2800 PATTON ROAD, ST. PAUL MN 55113
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Gary Blackford director 7700 FRANCE AVENUE SOUTH, EDINA MN 55435
Robert J Macdonald officer: Chief Retail Officer C/O OBALON THERAPEUTICS INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Daina Schmidt officer: Vice President of Marketing C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, SAN DIEGO CA 92008
Gilbert H Kliman 10 percent owner C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Arnold L Oronsky 10 percent owner C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Khaled Nasr 10 percent owner 467 FIRST STREET, SUITE 201, LOS ALTOS X1 94022
Interwest Partners X Lp 10 percent owner C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022